【ETF Trends】On April 1st, GF Hang Seng Biotechnology ETF increased by 6.57%, with shares decreasing by 79 million shares.

NightAirdropper · 2026-04-02T22:56:59+00:00

Securities Star News: On April 1st, GF Hang Seng Biotech ETF (159169) rose by 6.57%, with a trading volume of 103 million yuan. That day, the fund's shares decreased by 79 million, with the latest total shares at 304 million. Over the past 20 trading days, shares have decreased by 130 million. The net capital outflow on that day was 57.0654 million yuan (the capital flow is calculated as the difference between the asset net value on the day and the previous trading day's asset net value). The latest asset net value is calculated at 311 million yuan. GF Hang Seng Biotech ETF tracks the Hang Seng Biotech Index. Since its establishment on February 12, 2026, it has achieved an excess return of 6.19%, with a 1.39% excess return over the past month. The fund is managed by GF Fund Management, with Xia Haoyang and Wang Jiashi as fund managers.

NightAirdropper

2026-04-02 22:56:59

Securities Star news: On April 1, the GF Hang Seng Biotechnology ETF fund (159169) rose 6.57%, with trading volume of 103 million yuan. On the day, the fund’s shares decreased by 79 million shares, and the latest shares are 304 million. Over the past 20 trading days, shares decreased by 130 million. Net outflow of funds on the day was 57.0654 million yuan (the fund flow is calculated by subtracting the asset net value calculated on the current day from the asset net value calculated on the previous trading day). The latest calculated net asset value is 311 million yuan. The GF Hang Seng Biotechnology ETF fund tracks the Hang Seng Biotechnology Index. Since its inception (2026-02-12), the excess return has been 6.19%; over the past one month, the excess return has been 1.39%. The manager is GF Fund Management Co., Ltd., and the fund managers are Xia Haoyang and Wang Jiasi.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.